No Data
No Data
No Data
Daiko Pharmaceuticals Research Memo (3): Change of policy to a two-factory production system for the pharmaceutical business. "Cleverin" targets students preparing for examinations.
■ Daiyuki Pharmaceuticals <4574> Topics 1. Pharmaceutical Business: Strengthening Supply Capability and Smooth Progress of Price Increases The external environment of the pharmaceutical business is favorable. The increase in opportunities to go out and the demand from inbound are tailwinds, and the domestic antidiarrheal market is surpassing the pre-COVID level. The stable supply of the company has been the key to expanding market share, and the strengthening of shift production systems at the Suita and Oguni factories, as well as the launch of the packaging line for "Seirogan Sugar-coated A" at the Kyoto factory, have been prepared so far.
Daiko Pharmaceutical Research Memo (2): Increased revenue and profit for the fiscal year ending December 2024. Revised upward forecast for operating and ordinary profit.
For the fiscal year ending December 2024, we project revenue of 680 million yen (+11.1% YoY), operating profit of 550 million yen (compared to a loss of 1,005 million yen in the previous year), ordinary profit of 590 million yen (compared to a loss of 1,248 million yen in the previous year), and net income attributable to the parent company's shareholders of 550 million yen (compared to a loss of 3,611 million yen in the previous year).
Daiko Pharmaceuticals Research Memo (1): Achieved profitability for the first time in four quarters in the second quarter of the fiscal year ending December 2024.
Daikou Yakuhin Co., Ltd. <4574> operates a pharmaceutical business centered around "Seirogan" and "Seirogan Sugar-Coated A" and an infection management business centered around the "Cleverin" series of virus removal, sterilization, and deodorization products. In the second quarter of the fiscal year ending December 2024, the revenue was 2,860 million yen (an increase of 14.9% compared to the same period of the previous year), operating profit was 482 million yen (compared to a loss of 396 million yen in the same period of the previous year), ordinary profit was 528 million yen (compared to a loss of 510 million yen in the same period of the previous year), and net profit attributable to the parent company shareholders was
Taiko Pharmaceutical: Consolidated financial statements for the second quarter (interim period) of the fiscal year ending December 2024 (FY2024).
Daiko Yakuhin: Double-digit revenue growth in the second quarter, with each stage of profit turning black. The pharmaceutical business is progressing smoothly in terms of both revenue and profit.
Daiko Yakuhin <4574> announced its consolidated financial results for the second quarter of the fiscal year ending December 2024 (January-June 24). Revenue increased by 14.9% YoY to 2.86 billion yen, operating profit was 0.482 billion yen (compared to a loss of 0.396 billion yen in the same period last year), ordinary profit was 0.528 billion yen (compared to a loss of 0.51 billion yen in the same period last year), and net profit for the period attributable to the parent company's shareholders was 0.764 billion yen (compared to a loss of 0.514 billion yen in the same period last year). The pharmaceutical business revenue increased by 25.5% YoY to 2.654 billion yen, with segment profit.
Daiko Yakuhin - Revision of consolidated performance estimates and recording of impairment losses in the pharmaceutical business.
Daiko Yakuhin <4574> has revised its financial estimates for the fiscal year ending December 2024 and has decided to restructure its production system in the pharmaceutical business. Revenue is expected to remain at JPY 6.8 billion, operating profit expected to increase by 34.1% to JPY 0.55 billion compared to the previous estimate, ordinary profit expected to increase by 63.9% to JPY 59 billion, and net income attributable to the parent company shareholders expected to remain at JPY 0.55 billion, thanks to the strong demand for pharmaceuticals.
No Data
No Data